BrightGene's Dual GLP-1/GIP Agonist BGM0504 Shows Promise in Phase 2 Diabetes and Obesity Trials at ADA25

on

BrightGene presented positive Phase 2 results for its dual GLP-1/GIP receptor agonist BGM0504 at the 85th American Diabetes Association (ADA) Scientific Sessions in June 2025134.

In a study of 67 patients with type 2 diabetes, once-weekly subcutaneous BGM0504 (across three dose levels) was compared to semaglutide (the active ingredient in Wegovy and Ozempic) and placebo23.

BGM0504 achieved dose-dependent reductions in HbA1c (up to 2.48% after 12 weeks), outperforming semaglutide (1.43%) and placebo (0.28%); similar trends were observed for body weight and metabolic risk reduction23.

Reported weight loss with BGM0504 ranged from 10.77% to 19.78% across the three doses in these trials2.

BGM0504 showed significant weight management benefits in overweight and obese individuals, including those without diabetes, and was considered to have best-in-class potential for weight and metabolic risk reduction1.

BrightGene is conducting an ongoing head-to-head trial of BGM0504 against tirzepatide (Eli Lilly's Zepbound/Mounjaro) in obesity24.

The drug demonstrated robust safety and tolerability, with analysts noting clear improvements over current GLP-1 therapies in both glycemic control and weight loss4.

In addition to BGM0504, BrightGene presented preclinical data for a novel amylin analog (BGM1812), which also showed promise for future obesity treatment, especially in combination with GLP-1/GIP dual agonists1.

Sources:

1. https://www.biospace.com/press-releases/brightgene-presents-positive-phase-2-data-for-dual-glp-1r-gipr-agonist-for-weight-management-and-type-2-diabetes-and-preclinical-data-for-novel-amylin-analog-at-american-diabetes-associations-85th-scientific-sessions

2. https://www.fiercebiotech.com/biotech/brightgene-tops-novo-drug-diabetes-ahead-zepbound-showdown

3. https://firstwordpharma.com/story/5975593

4. https://www.thepharmaletter.com/pharmaceutical/brightgene-posts-strong-phase-ii-results-for-dual-agonist-drug